DNX Corp. other research news

The company's wholly owned preclinical contract testing subsidiary, Pharmakon Research International Inc., has developed a mouse that expresses human cholesterol ester transfer protein (CETP). The protein, which shuttles cholesterol in the bloodstream from HDL to LDL, is believed to hasten hardening of the arteries. While the evidence is primarily conjectural, the company told BioCentury, people with atherosclerosis do show elevated levels of the protein.

The mouse is intended as a screen for potential new treatments for heart disease. ...